These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 15983549

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. [Therapeutic effect of allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens on hematological malignancies].
    Yuan X, Sun ZM, Liu HL, Geng LQ, Wang ZY, Tong J, Yao W.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):614-7. PubMed ID: 18549640
    [Abstract] [Full Text] [Related]

  • 43. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
    Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Socié G, ATG-Fresenius Trial Group.
    Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
    [Abstract] [Full Text] [Related]

  • 44. Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation.
    Loren AW, Luger SM, Stadtmauer EA, Tsai DE, Schuster S, Nasta SD, Goldstein SC, Perl A, Orloff G, Oliver JC, Green J, Emerson SG, Porter DL.
    Bone Marrow Transplant; 2005 May; 35(9):921-6. PubMed ID: 15765118
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Comparison of calcineurin inhibitors in combination with conventional methotrexate, reduced methotrexate, or mycophenolate mofetil for prophylaxis of graft-versus-host disease after umbilical cord blood transplantation.
    Yoshida S, Ohno Y, Nagafuji K, Yoshimoto G, Sugio T, Kamimura T, Ohta T, Takase K, Henzan H, Muta T, Iwasaki H, Ogawa R, Eto T, Akashi K, Miyamoto T.
    Ann Hematol; 2019 Nov; 98(11):2579-2591. PubMed ID: 31628517
    [Abstract] [Full Text] [Related]

  • 47. Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation.
    Burroughs L, Mielcarek M, Leisenring W, Sandmaier BM, Maloney DG, Baron F, Martin PJ, Flowers ME, Forman SJ, Chauncey TR, Bruno B, Storb R.
    Transplantation; 2006 Mar 27; 81(6):818-25. PubMed ID: 16570002
    [Abstract] [Full Text] [Related]

  • 48. Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients.
    Kurata K, Yakushijin K, Okamura A, Yamamori M, Ichikawa H, Sakai R, Mizutani Y, Kakiuchi S, Miyata Y, Kitao A, Kawamoto S, Matsuoka H, Murayama T, Minami H.
    Cancer Chemother Pharmacol; 2018 May 27; 81(5):839-846. PubMed ID: 29511796
    [Abstract] [Full Text] [Related]

  • 49. Long-term follow-up of a prospective randomized trial comparing CYA and MTX with CYA and mycophenolate mofetil for GVHD prophylaxis in myeloablative sibling donor hematopoietic cell transplantation.
    Hamilton BK, Bolwell B, Kalaycio M, Rybicki L, Hanna R, Sobecks R, Pohlman B, Andresen S, Dean R, Duong H, Hill B, Copelan E.
    Bone Marrow Transplant; 2013 Nov 27; 48(12):1578-80. PubMed ID: 23749105
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies.
    Messina G, Giaccone L, Festuccia M, Irrera G, Scortechini I, Sorasio R, Gigli F, Passera R, Cavattoni I, Filippi AR, Schianca FC, Pini M, Risitano AM, Selleri C, Levis A, Mordini N, Gallamini A, Pastano R, Casini M, Aglietta M, Montanari M, Console G, Boccadoro M, Ricardi U, Bruno B, Gruppo Italiano Trapianti di Midollo.
    Biol Blood Marrow Transplant; 2012 Oct 27; 18(10):1600-7. PubMed ID: 22484666
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation.
    Jenke A, Renner U, Richte M, Freiberg-Richter J, Platzbecker U, Helwig A, Thiede HM, Schäfer-Eckart K, Ehninger G, Bornhäuser M.
    Clin Transplant; 2001 Jun 27; 15(3):176-84. PubMed ID: 11389708
    [Abstract] [Full Text] [Related]

  • 55. Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trial.
    Mevorach D, Zuckerman T, Reiner I, Shimoni A, Samuel S, Nagler A, Rowe JM, Or R.
    Biol Blood Marrow Transplant; 2014 Jan 27; 20(1):58-65. PubMed ID: 24140121
    [Abstract] [Full Text] [Related]

  • 56. Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation.
    Johnston L, Florek M, Armstrong R, McCune JS, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Sheehan K, Lavori P, Negrin R.
    Bone Marrow Transplant; 2012 Apr 27; 47(4):581-8. PubMed ID: 21552302
    [Abstract] [Full Text] [Related]

  • 57. Mycophenolate mofetil administered every 8 hours in combination with tacrolimus is efficacious in the prophylaxis of acute graft versus host disease in childhood, adolescent, and young adult allogeneic stem cell transplantation recipients.
    Militano O, Ozkaynak MF, Mehta B, van deVen C, Hamby C, Cairo MS.
    Pediatr Blood Cancer; 2018 Aug 27; 65(8):e27091. PubMed ID: 29667720
    [Abstract] [Full Text] [Related]

  • 58. Tailoring the GVHD prophylaxis regimen according to transplantation associated toxicities-Substituting the 3rd dose of methotrexate to mycophenolate mofetil.
    Ram R, Herscovici C, Dahan D, Israeli M, Dreyer J, Peck A, Shpilberg O, Yeshurun M.
    Leuk Res; 2014 Aug 27; 38(8):913-7. PubMed ID: 24939215
    [Abstract] [Full Text] [Related]

  • 59. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
    Carnevale-Schianca F, Caravelli D, Gallo S, Coha V, D'Ambrosio L, Vassallo E, Fizzotti M, Nesi F, Gioeni L, Berger M, Polo A, Gammaitoni L, Becco P, Giraudo L, Mangioni M, Sangiolo D, Grignani G, Rota-Scalabrini D, Sottile A, Fagioli F, Aglietta M.
    Biol Blood Marrow Transplant; 2017 Mar 27; 23(3):459-466. PubMed ID: 28039079
    [Abstract] [Full Text] [Related]

  • 60. Efficacy of tacrolimus/mycophenolate mofetil as acute graft-versus-host disease prophylaxis and the impact of subtherapeutic tacrolimus levels in children after matched sibling donor allogeneic hematopoietic cell transplantation.
    Offer K, Kolb M, Jin Z, Bhatia M, Kung AL, George D, Garvin JH, Robinson C, Sosna J, Karamehmet E, Satwani P.
    Biol Blood Marrow Transplant; 2015 Mar 27; 21(3):496-502. PubMed ID: 25536217
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.